放射線治療市場 – 2030年までの世界予測

Report Overview

The global radiotherapy market is projected to reach USD 9.62 billion by 2030 from USD 7.21 billion in 2024, growing at a CAGR of 4.9% during the forecast period.

世界の放射線治療市場は、2024年の72億1,000万米ドルから2030年までに96億2,000万米ドルに達すると予測されており、予測期間中に4.9%のCAGRで成長します。

The technological advancements of radiotherapy technologies and systems is one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of radiotherapy products affects the growth of the radiotherapy market.

“The external beam radiotherapy  segment to hold the largest share of the market in 2024.”

Based on technology, radiotherapy is segmented into external beam radiotherapy, internal beam radiotherapy/ brachytherapy. The external beam radiotherapy segment is expected to dominate the radiotherapy market during the forecast period. The external beam radiotherapy segment is further divided into LINACs, Particle therapy and Conventional cobalt-60 teletherapy. With the growing prevalence of cancer, system and software enhancements, and the increasing adoption of external beam radiotherapy devices worldwide leads to the growth of this market segment.

“The external beam radiotherapy procedures segment to hold the largest share of the market in 2024.”

Based on procedure, the Radiotherapy market is segmented into external beam radiotherapy (EBRT) procedures and internal beam radiotherapy (IBRT)/brachytherapy procedures. The radiotherapy market is expected to be dominated by external beam radiotherapy procedures segment during the forecast period. The external beam radiotherapy procedures are expected to grow due to increased precision & accuracy of tumor targeting in this therapy..

“The hospitals companies segment to hold the largest share of the market in 2024.”

The end user market is segmented into hospitals and independent radiotherapy centres. Hospitals accounted for the largest share of the global radiotherapy market in 2023 during the forecasted years. This can be attributed to the major applications and large demand of radiotherapy accounted by hospital sector and the growing number of hospitals in emerging countries.

“The market in the APAC region is expected to register highest growth rate for Radiotherapy in 2024.”

The radiotherapy market covers five key geographies—North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for radiotherapy was held by the market in the North American region, comprising the US and Canada. On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. The increasing market penetration opportunities in emerging APAC countries led to the growth of the radiotherapy market in this region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1– 48%, Tier 2– 36%, and Tier 3– 16%
• By Designation: Directors– 14%, C-level– 10%, and Others– 76%
• By Region: North America– 40%, Europe– 32%, Asia Pacific– 20%, Latin America- 5%, MEA- 3%

The prominent players in the Radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage

This report studies the radiotherapy market based on system, software & service, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (Advancements in radiotherapy treatment technology, Growing patient population, Increasing initiatives to promote radiotherapy awareness, Growing use of particle therapy for cancer treatment), restraints (High cost of advanced lab consumables, Environmental sustainability concerns), opportunities (Lack of adequate healthcare infrastructure, High capital cost of radiotherapy, Complexity of radiotherapy), and challenges (Dearth of skilled personnel, Difficulties in visualizing tumors during radiotherapy, Risk of Radiation Exposure) influencing the growth of the radiotherapy market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the radiotherapy market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the radiotherapy market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

Table of Contents

1               INTRODUCTION              29

1.1           STUDY OBJECTIVES       29

1.2           MARKET DEFINITION   29

1.3           MARKET SCOPE                30

1.3.1        MARKETS COVERED AND REGIONS CONSIDERED                 30

1.3.2        INCLUSIONS & EXCLUSIONS       31

1.3.3        YEARS CONSIDERED      32

1.3.4        CURRENCY CONSIDERED            32

1.4           MARKET STAKEHOLDERS            32

1.5           SUMMARY OF CHANGES               33

2               RESEARCH METHODOLOGY       34

2.1           RESEARCH DATA              34

2.1.1        SECONDARY DATA          35

2.1.1.1    List of secondary sources    36

2.1.2        PRIMARY DATA 37

2.1.2.1    Key data from primary sources           37

2.2           MARKET ESTIMATION METHODOLOGY               39

2.2.1        REVENUE MAPPING-BASED MARKET ESTIMATION                 40

2.2.2        USAGE-BASED MARKET ESTIMATION    42

2.2.3        PRIMARY RESEARCH VALIDATION           43

2.3           DATA TRIANGULATION AND MARKET BREAKDOWN                 44

2.4           RESEARCH ASSUMPTIONS           45

2.4.1        STUDY ASSUMPTIONS  45

2.5           RESEARCH LIMITATIONS             45

2.6           RISK ASSESSMENT           46

3               EXECUTIVE SUMMARY  47

4               PREMIUM INSIGHTS       51

4.1           RADIOTHERAPY MARKET OVERVIEW    51

4.2           EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)      52

4.3           EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET,

BY TYPE AND REGION (2022)      52

4.4           RADIOTHERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              53

4.5           RADIOTHERAPY MARKET: REGIONAL MIX, 2022–2030 (USD MILLION) 54

5               MARKET OVERVIEW       55

5.1           INTRODUCTION              55

5.2           MARKET DYNAMICS       55

5.2.1        DRIVERS               56

5.2.1.1    Advancements in radiotherapy treatment         56

5.2.1.2    Growing patient population                57

5.2.1.3    Increasing initiatives to promote radiotherapy awareness                 57

5.2.1.4    Growing use of particle therapy for cancer treatment    58

5.2.2        RESTRAINTS      58

5.2.2.1    Lack of adequate healthcare infrastructure      58

5.2.2.2    High capital cost of radiotherapy       59

5.2.2.3    Complexity of radiotherapy                 59

5.2.3        OPPORTUNITIES              60

5.2.3.1    Emerging economies            60

5.2.3.2    Favorable changes in US radiotherapy payment model 60

5.2.3.3    Government and private investments to meet rising demand for cancer treatment   61

5.2.4        CHALLENGES    61

5.2.4.1    Dearth of skilled personnel 61

5.2.4.2    Difficulties in visualizing tumors during radiotherapy   62

5.2.4.3    Risk of radiation exposure   62

5.3           REGULATORY ANALYSIS               63

5.3.1        REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS             63

5.3.2        REGULATORY LANDSCAPE         65

5.3.2.1    North America      65

5.3.2.1.1 US           65

5.3.2.1.2 Canada   66

5.3.2.2    Europe   67

5.3.2.3    Asia Pacific            68

5.3.2.3.1 China      68

5.3.2.3.2 Japan      68

5.3.2.3.3 India       69

5.4           REIMBURSEMENT SCENARIO     70

5.5           VALUE CHAIN ANALYSIS               71

5.5.1        RESEARCH & DEVELOPMENT    72

5.5.2        PROCUREMENT & PRODUCT DEVELOPMENT   72

5.5.3        MARKETING, SALES, AND DISTRIBUTION            72

5.6           SUPPLY CHAIN ANALYSIS             73

5.6.1        PROMINENT COMPANIES            73

5.6.2        SMALL & MEDIUM-SIZED ENTERPRISES 73

5.6.3        END USERS         73

5.7           ECOSYSTEM ANALYSIS  74

5.8           PORTER’S FIVE FORCES ANALYSIS           75

5.8.1        INTENSITY OF COMPETITIVE RIVALRY 76

5.8.2        BARGAINING POWER OF SUPPLIERS       76

5.8.3        BARGAINING POWER OF BUYERS             76

5.8.4        THREAT OF SUBSTITUTES          76

5.8.5        THREAT OF NEW ENTRANTS      76

5.9           KEY STAKEHOLDERS & BUYING CRITERIA            77

5.9.1        KEY STAKEHOLDERS IN BUYING PROCESS           77

5.9.2        KEY BUYING CRITERIA  78

5.10         TRADE ANALYSIS             79

5.10.1      IMPORT DATA  79

5.10.2      EXPORT DATA  80

5.11         PATENT ANALYSIS          81

5.12         PRICING ANALYSIS          83

5.12.1      AVERAGE SELLING PRICE, BY PRODUCT               83

5.12.2      AVERAGE SELLING PRICE, BY COUNTRY               84

5.13         TECHNOLOGY ANALYSIS             86

5.13.1      KEY TECHNOLOGIES     86

5.13.1.1  Linear accelerators (LINACs)            86

5.13.1.2  Image-guided radiotherapy (IGRT)  86

5.13.1.3  Intensity-modulated radiotherapy (IMRT)      86

5.13.1.4  Particle therapy    86

5.13.1.5  Surface-guided radiotherapy (SGRT)               87

5.13.2      COMPLEMENTARY TECHNOLOGIES       87

5.13.2.1  Chemotherapy       87

5.13.2.2  Immunotherapy    87

5.13.2.3  Hyperthermia therapy          87

5.13.3      ADJACENT TECHNOLOGIES       88

5.13.3.1  Medical imaging technologies            88

5.13.3.2  Radioisotope production technologies               88

5.13.3.3  Systematic radiotherapy      88

5.13.3.4  Theranostics          89

5.14         CASE STUDY ANALYSIS 89

5.15         KEY CONFERENCES & EVENTS, 2024–2025              89

5.16         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       91

5.17         INVESTMENT & FUNDING SCENARIO     91

5.18         UNMET NEEDS 93

5.19         IMPACT OF GENERATIVE AI ON RADIOTHERAPY MARKET               94

6               RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE           95

6.1           INTRODUCTION              96

6.2           SYSTEMS              96

6.2.1        CONTINUOUS DEVELOPMENT OF ADVANCED TECHNOLOGIES TO BOOST MARKET     96

6.3           SOFTWARE & SERVICES 97

6.3.1        INCREASING DEMAND FOR PRECISE AND EFFECTIVE CANCER TREATMENT TO SUPPORT MARKET GROWTH                 97

7               RADIOTHERAPY MARKET, BY TECHNOLOGY     99

7.1           INTRODUCTION              100

7.2           EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES                 100

7.2.1        LINACS 101

7.2.1.1    Conventional LINACs         102

7.2.1.1.1 Long treatment duration to limit adoption       102

7.2.1.2    Stereotactic advanced electron/cobalt-60 LINACs         103

7.2.1.2.1 CyberKnife             104

7.2.1.2.1.1              Precise radiation delivery with robotic correction capabilities to drive market 104

7.2.1.2.2 Gamma Knife        105

7.2.1.2.2.1              Ongoing product development and launches to support growth    105

7.2.1.2.3 TomoTherapy       106

7.2.1.2.3.1              High installation and maintenance costs to limit adoption 106

7.2.1.3    MRI LINACs         107

7.2.1.3.1 Real-time imaging advantage to propel growth               107

7.2.2        PARTICLE THERAPY       108

7.2.2.1    Cyclotrons              109

7.2.2.1.1 Enhanced outcomes and other advantages to boost adoption                 109

7.2.2.2    Synchrotrons         110

7.2.2.2.1 Increasing investments in synchrotron facilities to drive market                 110

7.2.2.3    Synchrocyclotrons                 110

7.2.2.3.1 High space requirements to limit widespread adoption 110

7.2.3        CONVENTIONAL COBALT-60 TELETHERAPY      111

7.2.3.1    Complex dose delivery planning and radiation exposure to limit market adoption   111

7.3           INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY                 112

7.3.1        SEEDS   113

7.3.1.1    Adverse side-effects associated with seeds to limit adoption                 113

7.3.2        AFTERLOADERS               114

7.3.2.1    Proper positioning and better control of isotopes in modern afterloaders to drive demand              114

7.3.3        IORT SYSTEMS  115

7.3.3.1    Rising adoption of electronic brachytherapy procedures to support growth      115

7.3.4        APPLICATORS   116

7.3.4.1    High risk of radiation exposure in manual applicators to limit growth    116

8               RADIOTHERAPY MARKET, BY APPLICATION       118

8.1           INTRODUCTION              119

8.2           EXTERNAL BEAM RADIOTHERAPY APPLICATIONS                 119

8.2.1        PROSTATE CANCER        120

8.2.1.1    High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth               120

8.2.2        BREAST CANCER              121

8.2.2.1    Therapeutic benefits of EBRT to drive market                121

8.2.3        LUNG CANCER  122

8.2.3.1    High prevalence of lung cancer and efficiency of EBRT to drive market    122

8.2.4        HEAD & NECK CANCER 123

8.2.4.1    Noninvasive treatment of head & neck cancers to drive market                 123

8.2.5        COLORECTAL CANCER 124

8.2.5.1    High incidence of colorectal cancer to support market growth                 124

8.2.6        OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS 125

8.3           INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS 126

8.3.1        PROSTATE CANCER        128

8.3.1.1    Precision of brachytherapy to drive market      128

8.3.2        GYNECOLOGICAL CANCER         129

8.3.2.1    Availability of alternatives to hinder adoption of brachytherapy                 129

8.3.3        BREAST CANCER              129

8.3.3.1    Wide usage as replacement for traditional EBRT to drive market                 129

8.3.4        CERVICAL CANCER         130

8.3.4.1    Effectiveness of combined brachytherapy-chemotherapy procedures to support adoption         130

8.3.5        PENILE CANCER                131

8.3.5.1    Rising awareness and effectiveness of brachytherapy to drive market    131

8.3.6        OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS        132

9               RADIOTHERAPY MARKET, BY PROCEDURE         134

9.1           INTRODUCTION              135

9.2           EXTERNAL BEAM RADIOTHERAPY           135

9.2.1        IMAGE-GUIDED RADIOTHERAPY             136

9.2.1.1    Growing demand in treating deep-seated tumors to drive market                 136

9.2.2        INTENSITY-MODULATED RADIOTHERAPY          137

9.2.2.1    Advantages over 2D and 3D-CRT to boost adoption     137

9.2.3        3D CONFORMAL RADIOTHERAPY            138

9.2.3.1    High precision and minimal damage to nearby tissues to boost adoption 138

9.2.4        STEREOTACTIC RADIOTHERAPY              139

9.2.4.1    Minimally invasive procedure to drive end-user preference                 139

9.2.5        PARTICLE THERAPY       140

9.2.5.1    High usage as primary mode of cancer treatment to sustain market growth       140

9.2.6        OTHER EXTERNAL BEAM RADIOTHERAPY PROCEDURES    141

9.3           INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY                 142

9.3.1        LDR BRACHYTHERAPY  143

9.3.1.1    Low risk of radiation exposure to surrounding tissues to drive adoption 143

9.3.2        HDR BRACHYTHERAPY 144

9.3.2.1    Possibility of tissue injury to affect adoption   144

9.3.3        PDR BRACHYTHERAPY  145

9.3.3.1    Combination of advantages to boost growth    145

10            RADIOTHERAPY MARKET, BY END USER               146

10.1         INTRODUCTION              147

10.2         HOSPITALS         147

10.2.1      HOSPITALS TO DOMINATE END-USER MARKET                 147

10.3         INDEPENDENT RADIOTHERAPY CENTERS           148

10.3.1      LOWER OPERATING COSTS AND CONVENIENCE TO SUPPORT MARKET GROWTH     148

11            RADIOTHERAPY MARKET, BY REGION   150

11.1         INTRODUCTION              151

11.2         NORTH AMERICA             153

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 158

11.2.2      US           159

11.2.2.1  Changes in reimbursement scenario to drive growth     159

11.2.3      CANADA               161

11.2.3.1  Favorable initiatives from government and private organizations to boost market     161

11.3         EUROPE               163

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      168

11.3.2      GERMANY           169

11.3.2.1  Availability of novel radiotherapy products to drive market                 169

11.3.3      FRANCE                171

11.3.3.1  Presence of advanced healthcare system to augment growth                 171

11.3.4      UK          173

11.3.4.1  High incidence of cancer to drive market         173

11.3.5      SPAIN    175

11.3.5.1  Growing research activities on cancer care to promote growth                 175

11.3.6      ITALY    177

11.3.6.1  Rising clinical trials and research activities in hospitals and universities to support growth            177

11.3.7      REST OF EUROPE             179

11.4         ASIA PACIFIC     180

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 187

11.4.2      JAPAN   187

11.4.2.1  Rising geriatric population to encourage growth             187

11.4.3      CHINA  189

11.4.3.1  Growing partnerships among market players to support growth                 189

11.4.4      INDIA    191

11.4.4.1  Increasing preference for minimally invasive treatment to propel market    191

11.4.5      SOUTH KOREA  193

11.4.5.1  Increasing incidence of cancer to support market           193

11.4.6      AUSTRALIA         195

11.4.6.1  Growing cancer cases to fuel market 195

11.4.7      REST OF ASIA PACIFIC   197

11.5         LATIN AMERICA                199

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 204

11.5.2      BRAZIL 204

11.5.2.1  Increasing prevalence of cancer to fuel market                204

11.5.3      MEXICO                206

11.5.3.1  Rising target population to boost market growth            206

11.5.4      REST OF LATIN AMERICA             208

11.6         MIDDLE EAST & AFRICA                210

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 215

11.6.2      GCC COUNTRIES              215

11.6.2.1  Booming medical tourism to expedite growth 215

11.6.3      REST OF MIDDLE EAST & AFRICA             217

12            COMPETITIVE LANDSCAPE         219

12.1         INTRODUCTION              219

12.2         KEY PLAYER STRATEGY/RIGHT TO WIN                219

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET      219

12.3         REVENUE ANALYSIS, 2019–2023  221

12.4         MARKET SHARE ANALYSIS, 2023                 221

12.4.1      EXTERNAL BEAM RADIOTHERAPY MARKET RANKING                 223

12.4.2      INTERNAL BEAM RADIOTHERAPY MARKET RANKING                 224

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 224

12.5.1      STARS   224

12.5.2      EMERGING LEADERS     224

12.5.3      PERVASIVE PLAYERS      225

12.5.4      PARTICIPANTS 225

12.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         226

12.5.5.1  Company footprint               226

12.5.5.2  Technology footprint           227

12.5.5.3  Application footprint            228

12.5.5.4  End-user footprint                229

12.5.5.5  Region footprint   229

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        230

12.6.1      PROGRESSIVE COMPANIES         230

12.6.2      RESPONSIVE COMPANIES            230

12.6.3      DYNAMIC COMPANIES  230

12.6.4      STARTING BLOCKS         231

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 232

12.7         COMPANY VALUATION & FINANCIAL METRICS 234

12.8         BRAND/PRODUCT COMPARISON             235

12.9         COMPETITIVE SCENARIO             236

12.9.1      PRODUCT LAUNCHES AND APPROVALS               236

12.9.2      DEALS  237

12.9.3      EXPANSIONS     238

13            COMPANY PROFILES      239

13.1         KEY PLAYERS     239

13.1.1      SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.) 239

13.1.1.1  Business overview 239

13.1.1.2  Products/Services/Solutions offered 240

13.1.1.3  Recent developments           242

13.1.1.3.1                Product approvals 242

13.1.1.3.2                Deals      242

13.1.1.4  MnM view              244

13.1.1.4.1                Key strengths        244

13.1.1.4.2                Strategic choices   244

13.1.1.4.3                Weaknesses & competitive threats     244

13.1.2      ELEKTA                245

13.1.2.1  Business overview 245

13.1.2.2  Products/Services/Solutions offered 246

13.1.2.3  Recent developments           247

13.1.2.3.1                Product launches and approvals         247

13.1.2.3.2                Deals      248

13.1.2.3.3                Expansions             250

13.1.2.4  MnM view              250

13.1.2.4.1                Key strengths        250

13.1.2.4.2                Strategic choices   250

13.1.2.4.3                Weaknesses & competitive threats     250

13.1.3      ACCURAY INCORPORATED         251

13.1.3.1  Business overview 251

13.1.3.2  Products/Services/Solutions offered 252

13.1.3.3  Recent developments           253

13.1.3.3.1                Product approvals 253

13.1.3.3.2                Deals      254

13.1.3.3.3                Expansions             255

13.1.3.4  MnM view              255

13.1.3.4.1                Key strengths        255

13.1.3.4.2                Strategic choices   255

13.1.3.4.3                Weaknesses & competitive threats     255

13.1.4      IBA WORLDWIDE             256

13.1.4.1  Business overview 256

13.1.4.2  Products/Services/Solutions offered 257

13.1.4.3  Recent developments           258

13.1.4.3.1                Products launches                 258

13.1.4.3.2                Deals      259

13.1.4.4  MnM view              260

13.1.4.4.1                Key strengths        260

13.1.4.4.2                Strategic choices   260

13.1.4.4.3                Weaknesses & competitive threats     260

13.1.5      VIEWRAY, INC.  261

13.1.5.1  Business overview 261

13.1.5.2  Products/Services/Solutions offered 262

13.1.5.3  Recent developments           263

13.1.5.3.1                Product approvals 263

13.1.5.3.2                Deals      263

13.1.6      BRAINLAB AG    265

13.1.6.1  Business overview 265

13.1.6.2  Products/Services/Solutions offered 265

13.1.7      PERSPECTIVE THERAPEUTICS   266

13.1.7.1  Business overview 266

13.1.7.2  Products/Services/Solutions offered 267

13.1.7.3  Recent developments           268

13.1.7.3.1                Deals      268

13.1.8      HITACHI LTD. (HITACHI HIGH-TECH CORPORATION)                 269

13.1.8.1  Business overview 269

13.1.8.2  Products/Services/Solutions offered 270

13.1.8.3  Recent developments           271

13.1.8.3.1                Deals      271

13.1.9      SUMITOMO HEAVY INDUSTRIES, LTD.  272

13.1.9.1  Business overview 272

13.1.9.2  Products/Services/Solutions offered 273

13.1.9.3  Recent developments           274

13.1.9.3.1                Product launches  274

13.1.9.3.2                Other developments             274

13.1.10   CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG)                275

13.1.10.1                 Business overview 275

13.1.10.2                 Products/Services/Solutions offered 277

13.1.10.3                 Recent developments           277

13.1.10.3.1             Products launches                 277

13.1.11   MIM SOFTWARE INC.     278

13.1.11.1                 Business overview 278

13.1.11.2                 Products/Services/Solutions offered 278

13.1.11.3                 Recent developments           279

13.1.11.3.1             Product launches and approvals         279

13.1.11.3.2             Deals      279

13.1.12   PANACEA MEDICAL TECHNOLOGIES PVT. LTD.                 280

13.1.12.1                 Business overview 280

13.1.12.2                 Products/Services/Solutions offered 280

13.1.12.3                 Recent developments           281

13.1.12.3.1             Product launches and approvals         281

13.1.13   PROVISION HEALTHCARE            282

13.1.13.1                 Business overview 282

13.1.13.2                 Products/Services/Solutions offered 282

13.1.14   MEVION MEDICAL SYSTEMS       283

13.1.14.1                 Business overview 283

13.1.14.2                 Products/Services/Solutions offered 283

13.1.14.3                 Recent developments           284

13.1.14.3.1             Product launches  284

13.1.14.3.2             Deals      284

13.1.15   RAYSEARCH LABORATORIES      286

13.1.15.1                 Business overview 286

13.1.15.2                 Products/Services/Solutions offered 287

13.1.15.3                 Recent developments           288

13.1.15.3.1             Product launches  288

13.1.15.3.2             Deals      288

13.1.16   KONINKLIJKE PHILIPS N.V.          290

13.1.16.1                 Business overview 290

13.1.16.2                 Products/Services/Solutions offered 291

13.1.16.3                 Recent developments           292

13.1.16.3.1             Product launches  292

13.1.16.3.2             Deals      292

13.2         OTHER PLAYERS              293

13.2.1      INTRAOP MEDICAL, INC.              293

13.2.2      OPTIVUS PROTON THERAPY, INC.           294

13.2.3      BEBIG MEDICAL               295

13.2.4      P-CURE 296

13.2.5      THERAGENICS CORPORATION 297

13.2.6      PROTOM INTERNATIONAL         298

13.2.7      DOS ISOFT SA    299

13.2.8      ISOAID, LLC        300

13.2.9      MAGNETTX ONCOLOGY SOLUTIONS LTD.          301

14            APPENDIX           302

14.1         DISCUSSION GUIDE        302

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                309

14.3         CUSTOMIZATION OPTIONS        311

14.4         RELATED REPORTS         311

14.5         AUTHOR DETAILS           312

LIST OF TABLES

TABLE 1                NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 63

TABLE 2                EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           63

TABLE 3                ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 64

TABLE 4                LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 64

TABLE 5                MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 64

TABLE 6                US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              66

TABLE 7                CLASS II PRESCRIBED EQUIPMENT CERTIFICATES  66

TABLE 8                JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA   68

TABLE 9                INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO 69

TABLE 10              CPT CODES FOR MAJOR RADIOTHERAPY TREATMENT MODALITIES          70

TABLE 11              REIMBURSEMENT FOR RADIOTHERAPY PROCEDURES PER COURSE,

2021 VS. 2022       70

TABLE 12              OPPS TECHNICAL PER PROCEDURE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022    71

TABLE 13              FREESTANDING PER COURSE NATIONAL AVERAGE MEDICARE REIMBURSEMENT, 2021 VS. 2022    71

TABLE 14              RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS           75

TABLE 15              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY DEVICES 77

TABLE 16              KEY BUYING CRITERIA FOR RADIOTHERAPY                 78

TABLE 17              IMPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2019−2023 (USD)                79

TABLE 18              EXPORT DATA FOR LINACS (HS CODE 902214), BY COUNTRY, 2019−2023 (USD)                80

TABLE 19              AVERAGE SELLING PRICE RANGE OF KEY PLAYERS FOR TOP TWO PRODUCTS (USD)          84

TABLE 20              AVERAGE SELLING PRICE TREND OF RADIOTHERAPY PRODUCTS, BY REGION, 2021–2023        85

TABLE 21              CASE STUDY: ENHANCING PATIENT SAFETY—SBRT’S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)       89

TABLE 22              RADIOTHERAPY MARKET: DETAILED LIST OF MAJOR CONFERENCES & EVENTS             89

TABLE 23              RADIOTHERAPY MARKET: CURRENT UNMET NEEDS  93

TABLE 24              RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE,

2022–2030 (USD MILLION)            96

TABLE 25              RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION)            97

TABLE 26              RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION,

2022–2030 (USD MILLION)            98

TABLE 27              RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            100

TABLE 28              EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE,

2022–2030 (USD MILLION)            101

TABLE 29              EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION,

2022–2030 (USD MILLION)            101

TABLE 30              LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            102

TABLE 31              LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)            102

TABLE 32              CONVENTIONAL LINACS MARKET, BY REGION, 2022–2030 (USD MILLION)            103

TABLE 33              STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 103

TABLE 34              STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 104

TABLE 35              CYBERKNIFE MARKET, BY REGION, 2022–2030 (USD MILLION) 105

TABLE 36              GAMMA KNIFE MARKET, BY REGION, 2022–2030 (USD MILLION) 106

TABLE 37              TOMOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)       107

TABLE 38              MRI LINACS MARKET, BY REGION, 2022–2030 (USD MILLION) 107

TABLE 39              PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2022–2030 (USD MILLION)            108

TABLE 40              PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)       108

TABLE 41              CYCLOTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)            109

TABLE 42              SYNCHROTRONS THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)          110

TABLE 43              SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            111

TABLE 44              CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            112

TABLE 45              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET,

BY TYPE, 2022–2030 (USD MILLION)         112

TABLE 46              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET,

BY REGION, 2022–2030 (USD MILLION)   113

TABLE 47              SEEDS MARKET, BY REGION, 2022–2030 (USD MILLION)            114

TABLE 48              AFTERLOADERS MARKET, BY REGION, 2022–2030 (USD MILLION)       115

TABLE 49              IORT SYSTEMS MARKET, BY REGION, 2022–2030 (USD MILLION) 116

TABLE 50              APPLICATORS MARKET, BY REGION, 2022–2030 (USD MILLION) 117

TABLE 51              RADIOTHERAPY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            119

TABLE 52              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE,

2022–2030 (USD MILLION)            120

TABLE 53              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION,

2022–2030 (USD MILLION)            120

TABLE 54              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION)            121

TABLE 55              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION)            122

TABLE 56              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER,

BY REGION, 2022–2030 (USD MILLION)   123

TABLE 57              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD & NECK CANCER, BY REGION, 2022–2030 (USD MILLION)          124

TABLE 58              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2030 (USD MILLION)          125

TABLE 59              OTHER EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)                 126

TABLE 60              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET,

BY TYPE, 2022–2030 (USD MILLION)         127

TABLE 61              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET,

BY REGION, 2022–2030 (USD MILLION)   127

TABLE 62              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION)                 128

TABLE 63              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2022–2030 (USD MILLION)            129

TABLE 64              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION)                 130

TABLE 65              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR CERVICAL CANCER, BY REGION, 2022–2030 (USD MILLION)                 131

TABLE 66              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PENILE CANCER, BY REGION, 2022–2030 (USD MILLION)                 132

TABLE 67              OTHER INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2022–2030 (USD MILLION)   133

TABLE 68              RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)            135

TABLE 69              EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)                136

TABLE 70              EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION,

2022–2030 (USD MILLION)            136

TABLE 71              IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)          137

TABLE 72              INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            138

TABLE 73              3D CONFORMAL RADIOTHERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            139

TABLE 74              STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)          140

TABLE 75              PARTICLE THERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)       141

TABLE 76              OTHER EBRT PROCEDURES MARKET, BY REGION, 2022–2030 (USD MILLION)          142

TABLE 77              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            142

TABLE 78              INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            143

TABLE 79              LDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)            144

TABLE 80              HDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)            144

TABLE 81              PDR BRACHYTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)            145

TABLE 82              RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)       147

TABLE 83              RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION)          148

TABLE 84              RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS,

BY REGION, 2022–2030 (USD MILLION)   149

TABLE 85              RADIOTHERAPY MARKET, BY REGION, 2022–2030 (USD MILLION)       151

TABLE 86              RADIOTHERAPY MARKET: INSTALLED BASE, 2024 (UNITS)      151

TABLE 87              NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            154

TABLE 88              NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            154

TABLE 89              NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            154

TABLE 90              NORTH AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            155

TABLE 91              NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 155

TABLE 92             NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,

2022–2030 (USD MILLION)            155

TABLE 93              NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         156

TABLE 94              NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,

BY TYPE, 2022–2030 (USD MILLION)         156

TABLE 95              NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)         157

TABLE 96              NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)            157

TABLE 97              NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY /BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)                158

TABLE 98              NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER,

2022–2030 (USD MILLION)            158

TABLE 99              NORTH AMERICA: MACROECONOMIC OUTLOOK           158

TABLE 100            NORTH AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025 159

TABLE 101            US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            160

TABLE 102            US: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            160

TABLE 103            US: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            160

TABLE 104            US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            161

TABLE 105            CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            162

TABLE 106            CANADA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            162

TABLE 107            CANADA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 162

TABLE 108            CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       163

TABLE 109            EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     164

TABLE 110            EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            164

TABLE 111            EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            164

TABLE 112            EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 165

TABLE 113            EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET,

BY TYPE, 2022–2030 (USD MILLION)         165

TABLE 114            EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,

2022–2030 (USD MILLION)            165

TABLE 115            EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       166

TABLE 116            EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)                 166

TABLE 117            EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)         167

TABLE 118            EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE,

2022–2030 (USD MILLION)            167

TABLE 119            EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)                168

TABLE 120            EUROPE: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)                168

TABLE 121            EUROPE: MACROECONOMIC OUTLOOK                 169

TABLE 122            EUROPE: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025             169

TABLE 123            GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            170

TABLE 124            GERMANY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            170

TABLE 125            GERMANY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 171

TABLE 126            GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       171

TABLE 127            FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            172

TABLE 128            FRANCE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            172

TABLE 129            FRANCE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 172

TABLE 130            FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       173

TABLE 131            UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            173

TABLE 132            UK: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            174

TABLE 133            UK: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            174

TABLE 134            UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            174

TABLE 135            SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            175

TABLE 136            SPAIN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            176

TABLE 137            SPAIN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 176

TABLE 138            SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       176

TABLE 139            ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            177

TABLE 140            ITALY: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            178

TABLE 141            ITALY: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 178

TABLE 142            ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       178

TABLE 143            REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            179

TABLE 144            REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            179

TABLE 145            REST OF EUROPE: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            180

TABLE 146            REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         180

TABLE 147            ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     182

TABLE 148            ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            182

TABLE 149            ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            183

TABLE 150            ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)       183

TABLE 151            ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 184

TABLE 152            ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,

2022–2030 (USD MILLION)            184

TABLE 153            ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         184

TABLE 154            ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 185

TABLE 155            ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)         185

TABLE 156            ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE,

2022–2030 (USD MILLION)            186

TABLE 157            ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)                186

TABLE 158            ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2022–2030 (USD MILLION)     186

TABLE 159            ASIA PACIFIC: MACROECONOMIC OUTLOOK                 187

TABLE 160            ASIA PACIFIC: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025             187

TABLE 161            JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            188

TABLE 162            JAPAN: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            188

TABLE 163            JAPAN: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 188

TABLE 164            JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       189

TABLE 165            CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            190

TABLE 166            CHINA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            190

TABLE 167            CHINA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 190

TABLE 168            CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       191

TABLE 169            INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            192

TABLE 170            INDIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            192

TABLE 171            INDIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 192

TABLE 172            INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       193

TABLE 173            SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            194

TABLE 174            SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            194

TABLE 175            SOUTH KOREA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            195

TABLE 176            SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         195

TABLE 177            AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            196

TABLE 178            AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            196

TABLE 179            AUSTRALIA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)       197

TABLE 180            AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       197

TABLE 181            REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            198

TABLE 182            REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            198

TABLE 183            REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)                198

TABLE 184            REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       199

TABLE 185            LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            199

TABLE 186            LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            200

TABLE 187            LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            200

TABLE 188            LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            200

TABLE 189            LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 201

TABLE 190            LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE,

2022–2030 (USD MILLION)            201

TABLE 191            LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         201

TABLE 192            LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET,

BY TYPE, 2022–2030 (USD MILLION)         202

TABLE 193            LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)         202

TABLE 194            LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY PROCEDURE, 2022–2030 (USD MILLION)            203

TABLE 195            LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)                203

TABLE 196            LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER,

2022–2030 (USD MILLION)            203

TABLE 197            LATIN AMERICA: MACROECONOMIC OUTLOOK                 204

TABLE 198            LATIN AMERICA: ESTIMATED NUMBER OF NEW CANCER CASES, 2022–2025             204

TABLE 199            BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            205

TABLE 200            BRAZIL: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            205

TABLE 201            BRAZIL: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 205

TABLE 202            BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       206

TABLE 203            MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            206

TABLE 204            MEXICO: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            207

TABLE 205            MEXICO: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION) 207

TABLE 206            MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       207

TABLE 207            REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            208

TABLE 208            REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)                 208

TABLE 209            REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)                209

TABLE 210            REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       209

TABLE 211            MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION,

2022–2030 (USD MILLION)            210

TABLE 212            MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            211

TABLE 213            MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)                 211

TABLE 214            MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)                211

TABLE 215            MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            212

TABLE 216            MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            212

TABLE 217            MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)       212

TABLE 218            MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION) 213

TABLE 219            MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2022–2030 (USD MILLION)         213

TABLE 220            MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET,

BY PROCEDURE, 2022–2030 (USD MILLION)          214

TABLE 221            MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURE MARKET, BY TYPE, 2022–2030 (USD MILLION)                214

TABLE 222            MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER,

2022–2030 (USD MILLION)            214

TABLE 223            MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK           215

TABLE 224            MIDDLE EAST & AFRICA: ESTIMATED NUMBER OF NEW CANCER CASES,

2022–2025              215

TABLE 225            GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            216

TABLE 226            GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY MARKET, BY TYPE,

2022–2030 (USD MILLION)            216

TABLE 227            GCC COUNTRIES: LINACS MARKET, BY TYPE, 2022–2030 (USD MILLION)            216

TABLE 228            GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         217

TABLE 229            REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            217

TABLE 230            REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY MARKET,

BY TYPE, 2022–2030 (USD MILLION)         218

TABLE 231            REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE,

2022–2030 (USD MILLION)            218

TABLE 232            REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY MARKET, BY TYPE, 2022–2030 (USD MILLION)            218

TABLE 233            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN

RADIOTHERAPY MARKET            219

TABLE 234            RADIOTHERAPY MARKET: DEGREE OF COMPETITION 222

TABLE 235            RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT       227

TABLE 236            RADIOTHERAPY MARKET: APPLICATION FOOTPRINT       228

TABLE 237            RADIOTHERAPY MARKET: END-USER FOOTPRINT       229

TABLE 238            RADIOTHERAPY MARKET: REGION FOOTPRINT                 229

TABLE 239            RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS      232

TABLE 240            RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS                 233

TABLE 241            RADIOTHERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–OCTOBER 2024   236

TABLE 242            RADIOTHERAPY MARKET: DEALS, JANUARY 2021–OCTOBER 2024        237

TABLE 243            RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2021–OCTOBER 2024   238

TABLE 244            SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):

COMPANY OVERVIEW   239

TABLE 245            SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.): PRODUCTS/SERVICES/SOLUTIONS OFFERED                 240

TABLE 246            SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):

PRODUCT APPROVALS, JANUARY 2021–OCTOBER 2024  242

TABLE 247            SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):

DEALS, JANUARY 2021− OCTOBER 2024 242

TABLE 248            ELEKTA: COMPANY OVERVIEW 245

TABLE 249            ELEKTA: PRODUCTS/SERVICES/SOLUTIONS OFFERED             246

TABLE 250            ELEKTA: PRODUCTS LAUNCHES AND APPROVALS, JANUARY 2021−OCTOBER 2024       247

TABLE 251            ELEKTA: DEALS, JANUARY 2021−OCTOBER 2024                 248

TABLE 252            ELEKTA: EXPANSIONS, JANUARY 2021− OCTOBER 2024  250

TABLE 253            ACCURAY INCORPORATED: COMPANY OVERVIEW          251

TABLE 254            ACCURAY INCORPORATED: PRODUCTS/SERVICES/SOLUTIONS OFFERED    252

TABLE 255            ACCURAY INCORPORATED: PRODUCT APPROVALS,

JANUARY 2021−OCTOBER 2024 253

TABLE 256            ACCURAY INCORPORATED: DEALS, JANUARY 2021−OCTOBER 2024     254

TABLE 257            ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2021− OCTOBER 2024                 255

TABLE 258            IBA WORLDWIDE: COMPANY OVERVIEW                 256

TABLE 259            IBA WORLDWIDE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    257

TABLE 260            IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2021−OCTOBER 2024 258

TABLE 261            IBA WORLDWIDE: DEALS, JANUARY 2021−OCTOBER 2024     259

TABLE 262            VIEWRAY, INC.: COMPANY OVERVIEW   261

TABLE 263            VIEWRAY, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    262

TABLE 264            VIEWRAY, INC.: PRODUCT APPROVALS, JANUARY 2021−OCTOBER 2024 263

TABLE 265            VIEWRAY, INC.: DEALS, JANUARY 2021−OCTOBER 2024     263

TABLE 266            BRAINLAB AG: COMPANY OVERVIEW     265

TABLE 267            BRAINLAB AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED    265

TABLE 268            PERSPECTIVE THERAPEUTICS: COMPANY OVERVIEW          266

TABLE 269            PERSPECTIVE THERAPEUTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED    267

TABLE 270            PERSPECTIVE THERAPEUTICS: DEALS, JANUARY 2021−OCTOBER 2024 268

TABLE 271            HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY OVERVIEW                269

TABLE 272            HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): PRODUCTS/SERVICES/SOLUTIONS OFFERED                 270

TABLE 273            HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): DEALS,

JANUARY 2021− OCTOBER 2024                 271

TABLE 274            SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW   272

TABLE 275            SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS/SERVICES/

SOLUTIONS OFFERED   273

TABLE 276            SUMITOMO HEAVY INDUSTRIES LTD.: PRODUCT LAUNCHES,

JANUARY 2021−OCTOBER 2024 274

TABLE 277            SUMITOMO HEAVY INDUSTRIES LTD.: OTHER DEVELOPMENTS,

JANUARY 2021−OCTOBER 2024 274

TABLE 278            CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY OVERVIEW 275

TABLE 279            CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCTS/SERVICES/SOLUTIONS OFFERED    277

TABLE 280            CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): PRODUCT LAUNCHES, JANUARY 2021−OCTOBER 2024 277

TABLE 281            MIM SOFTWARE INC.: COMPANY OVERVIEW                 278

TABLE 282            MIM SOFTWARE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    278

TABLE 283            MIM SOFTWARE INC.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021−OCTOBER 2024 279

TABLE 284            MIM SOFTWARE INC.: DEALS, JANUARY 2021−OCTOBER 2024     279

TABLE 285            PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW   280

TABLE 286            PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SERVICES/

SOLUTIONS OFFERED   280

TABLE 287            PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021−OCTOBER 2024     281

TABLE 288            PROVISION HEALTHCARE: COMPANY OVERVIEW          282

TABLE 289            PROVISION HEALTHCARE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    282

TABLE 290            MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW          283

TABLE 291            MEVION MEDICAL SYSTEMS: PRODUCTS/SERVICES/SOLUTIONS OFFERED    283

TABLE 292            MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES,

JANUARY 2021−OCTOBER 2024 284

TABLE 293            MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2021−OCTOBER 2024     284

TABLE 294            RAYSEARCH LABORATORIES: COMPANY OVERVIEW          286

TABLE 295            RAYSEARCH LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED    287

TABLE 296            RAYSEARCH LABORATORIES: PRODUCT LAUNCHES,

JANUARY 2021−OCTOBER 2024 288

TABLE 297            RAYSEARCH LABORATORIES: DEALS, JANUARY 2021−OCTOBER 2024     288

TABLE 298            KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW          290

TABLE 299            KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    291

TABLE 300            KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021−OCTOBER 2024         292

TABLE 301            KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−OCTOBER 2024     292

TABLE 302            INTRAOP MEDICAL, INC.: COMPANY OVERVIEW                 293

TABLE 303            OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW          294

TABLE 304            BEBIG MEDICAL: COMPANY OVERVIEW                 295

TABLE 305            P-CURE: COMPANY OVERVIEW 296

TABLE 306            THERAGENICS CORPORATION: COMPANY OVERVIEW          297

TABLE 307            PROTOM INTERNATIONAL: COMPANY OVERVIEW          298

TABLE 308            DOSISOFT SA: COMPANY OVERVIEW     299

TABLE 309            ISOAID, LLC: COMPANY OVERVIEW        300

TABLE 310            MAGNETTX ONCOLOGY SOLUTIONS LTD.: COMPANY OVERVIEW   301

LIST OF FIGURES

FIGURE 1              RESEARCH DESIGN         34

FIGURE 2              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     38

FIGURE 3              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           40

FIGURE 4              MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2023)                42

FIGURE 5              RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY  43

FIGURE 6              DATA TRIANGULATION METHODOLOGY                 44

FIGURE 7              RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE,

2024 VS. 2030 (USD MILLION)      47

FIGURE 8              RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION)      48

FIGURE 9              EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE,

2024 VS. 2030 (USD MILLION)      48

FIGURE 10            RADIOTHERAPY MARKET SHARE, BY END USER, 2024 VS. 2030(%)                49

FIGURE 11            RADIOTHERAPY MARKET: REGIONAL SNAPSHOT          50

FIGURE 12            RISING CANCER PREVALENCE WORLDWIDE TO DRIVE MARKET GROWTH            51

FIGURE 13            INTENSITY-MODULATED RADIATION THERAPY TO HOLD LARGEST

SHARE OF MARKET IN 2024          52

FIGURE 14            LINACS HELD LARGEST SHARE OF EUROPEAN MARKET IN 2O23              52

FIGURE 15            CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       53

FIGURE 16            NORTH AMERICA WILL CONTINUE TO DOMINATE RADIOTHERAPY MARKET DURING FORECAST PERIOD                54

FIGURE 17            RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          55

FIGURE 18            PROJECTED INCREASE IN CANCER CASES, 2020 VS. 2040 57

FIGURE 19            RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS            72

FIGURE 20            RADIOTHERAPY MARKET: SUPPLY CHAIN ANALYSIS            73

FIGURE 21            RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS            74

FIGURE 22            RADIOTHERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS           75

FIGURE 23            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY    77

FIGURE 24            KEY BUYING CRITERIA FOR RADIOTHERAPY                 78

FIGURE 25            RADIOTHERAPY MARKET: TOP PATENT OWNERS/PATENTING TRENDS FOR PROTON BEAM THERAPY IN RECENT YEARS            81

FIGURE 26            RADIOTHERAPY MARKET: TOP PATENT OWNERS/PATENTING TRENDS FOR MEDICAL LINEAR ACCELERATORS IN RECENT YEARS         82

FIGURE 27            AVERAGE SELLING PRICE, BY PRODUCT, 2023 (USD)    83

FIGURE 28            AVERAGE SELLING PRICE OF RADIOTHERAPY PRODUCTS, BY COUNTRY,

2023 (USD)          84

FIGURE 29            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES           91

FIGURE 30            RADIOTHERAPY MARKET: NUMBER OF DEALS, BY KEY PLAYER,

2019–2023 (USD MILLION)            92

FIGURE 31            RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER,

2019–2023 (USD MILLION)            92

FIGURE 32            VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER,

2019–2023 (USD MILLION)            93

FIGURE 33            USE OF GEN AI IN RADIOTHERAPY MARKET                 94

FIGURE 34            NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT          153

FIGURE 35            ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT          181

FIGURE 36            REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2019−2023)   221

FIGURE 37            MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET (2023)                222

FIGURE 38            EXTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023                 223

FIGURE 39            INTERNAL BEAM RADIOTHERAPY MARKET RANKING, BY KEY PLAYER, 2023                 224

FIGURE 40            RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023         225

FIGURE 41            RADIOTHERAPY MARKET: COMPANY FOOTPRINT       226

FIGURE 42            RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023                231

FIGURE 43            EV/EBITDA OF KEY VENDORS   234

FIGURE 44            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS      234

FIGURE 45            RADIOTHERAPY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS            235

FIGURE 46            SIEMENS HEALTHINEERS AG (VARIAN MEDICAL SYSTEMS, INC.):

COMPANY SNAPSHOT   240

FIGURE 47            ELEKTA: COMPANY SNAPSHOT 246

FIGURE 48            ACCURAY INCORPORATED: COMPANY SNAPSHOT          252

FIGURE 49            IBA WORLDWIDE: COMPANY SNAPSHOT                 257

FIGURE 50            VIEWRAY, INC.: COMPANY SNAPSHOT   262

FIGURE 51            PERSPECTIVE THERAPEUTICS: COMPANY SNAPSHOT          267

FIGURE 52            HITACHI LTD. (HITACHI HIGH-TECH CORPORATION): COMPANY SNAPSHOT                270

FIGURE 53            SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT   273

FIGURE 54            CARL ZEISS MEDITEC AG (WHOLLY OWNED SUBSIDIARY OF CARL ZEISS AG): COMPANY SNAPSHOT                 276

FIGURE 55            RAYSEARCH LABORATORIES: COMPANY SNAPSHOT          287

FIGURE 56            KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT          291

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧